CIK 0001517022
- Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 208756903
- Phone
- +1 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-09-12 | Renaud Ronald C JR Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2014-08-18 | Maroni Bradley SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2014-07-28 | Clayman Michael D. Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2014-07-28 | GOWEN MAXINE Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2014-05-14 | Butler John P. President and CEO | Grant or award · Stock Option (Right to Buy) | +46,667 | 46,667 | ||
| 2014-05-14 | Amello Jason SVP, CFO & Treasurer | Grant or award · Stock Option (Right to Buy) | +21,667 | 21,667 | ||
| 2014-05-14 | Hadas Nicole R. VP General Counsel & Secretary | Grant or award · Stock Option (Right to Buy) | +16,667 | 16,667 | ||
| 2014-05-14 | Shalwitz Robert Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +21,667 | 21,667 | ||
| 2014-03-25 | Novartis Bioventures Ltd 10% owner | Purchase | +182,590 | $17.00 | $3.1M | 182,590 |
| 2014-03-25 | Novartis Bioventures Ltd 10% owner | Conversion | +3,223,174 | 3,405,764 | ||
| 2014-03-25 | Novartis Bioventures Ltd 10% owner | Conversion · Series A Convertible Preferred Stock | −257,031 | 0 | ||
| 2014-03-25 | Novartis Bioventures Ltd 10% owner | Conversion · Series B Convertible Preferred Stock | −347,831 | 0 | ||
| 2014-03-25 | Novartis Bioventures Ltd 10% owner | Conversion · Series C Convertible Preferred Stock | −708,647 | 0 | ||
| 2014-03-25 | WYZGA MICHAEL S Director | Purchase | +1,500 | $17.00 | $26K | 1,500 |
| 2014-03-25 | Shalwitz Robert Chief Medical Officer | Conversion | +12,560 | 247,540 | ||
| 2014-03-25 | Shalwitz Robert Chief Medical Officer | Conversion | +17,016 | 264,556 | ||
| 2014-03-25 | Shalwitz Robert Chief Medical Officer | Conversion · Series A Convertible Preferred Stock | −850 | 0 | ||
| 2014-03-25 | Shalwitz Robert Chief Medical Officer | Conversion · Series B Convertible Preferred Stock | −2,070 | 0 | ||
| 2014-03-25 | Shalwitz Robert Chief Medical Officer | Conversion · Series C Convertible Preferred Stock | −2,500 | 0 | ||
| 2014-03-25 | Shalwitz Robert Chief Medical Officer | Conversion · Series A Convertible Preferred Stock | −3,403 | 0 |
Page 29 of 30 · 590 trades